HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke
Study Details
Study Description
Brief Summary
Botulinum toxin produced beneficial effects in spasticity in the hemiplegic upper limb. This study will test if botulinum toxin injections at earlier phases (<or = 3 months) in spasticity improve functional and motor tests compared with late injections (>or = 6 months).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Outcome Measures
Primary Outcome Measures
- Deficiency, incapacity, handicap : Frenchay Arm test(post stroke arm function); Enjalbert test; []
- Box and blocks test []
- Enjalbert test []
- Modified Ashworth scale (upper limb) []
- Functional Independence Measure []
- Fugl-Meyer upper limb test []
- Clinical Global Impression (CGI) []
- 36-Item Short Form (SF-36) quality of life []
Secondary Outcome Measures
- Range of pain []
- Individual functional kinesitherapy []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Minimum age 18
-
Spastic hemiplegia after ischemic stroke (carotid occlusion) within the past 3 months.
-
Antispasticity medication stabilized for the last 30 days
-
Severe cognitive impairment such that patient is unable to provide scale assessment.
-
Significant spasticity impeding improvement by re-education for 2 months or less
-
Lack of muscular retraction defined by a minimal range of articular motion as :
-
finger : complete extension and rolling up
-
wrist : extension 40°/flexion : 45°
-
elbow : extension - 10°/flexion : 120°
-
shoulder : Enjalbert score 2 or more
-
Antagonist muscles (to spasticity) activity score 1 or more
-
Social Security benefits
Exclusion Criteria:
-
Ischemic stroke thought to be due to basilar or vertebral vessel occlusion
-
Known motor neuron or neuromuscular junction disease, disorders in which pain limits the ability to inject muscles (algodystrophy)
-
Absence of mobility in proximal part of upper limb that does not predict a functional gain
-
Minor stroke with non-disabling deficit or rapidly improving motor symptoms
-
other serious illness, e.g. severe hepatic, cardiac, or renal failure ; acute myocardial infarction ; or a complex disease that may confound treatment assessment
-
Treatment of spasticity by previous administration of botulinum toxin, if known
-
Known allergy to botulinum toxin
-
Currently participating in other research studies
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Clermont-Ferrand University Hospital | Clermont-Ferrand | Auvergne | France | 63000 |
Sponsors and Collaborators
- University Hospital, Clermont-Ferrand
- J. Rebeyrol Hospital in Limoges
- Rennes University Hospital
- Center of Physical Medicine and Rehabilitation (Notre Dame de Lourdes Center in Rennes)
- Saint Jacques Hospital in Nantes
- Centre Hospitalier Universitaire de Saint Etienne
- Centre Régional de Département de médecine physique et réadaptation CHU-C3RF in Angers
- Centre Hospitalier Universitaire de Besancon
Investigators
- Principal Investigator: Franck Durif, University Hospital, Clermont-Ferrand
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHU63-0003